Novo Nordisk A/S reports results for the quarter ended September 30 - Earnings Summary

Novo Nordisk A/S

04/11/2026 07:35

Novo Nordisk A/S NOVOb.CO reported quarterly adjusted earnings of DKK3.79​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of DKK4.50.  The mean expectation of fourteen analysts for the quarter was for earnings of DKK4.82 per share. Wall Street expected results to range from DKK4.01  to DKK5.34 per share.
Revenue rose 5.6% to DKK79.20 billion from a year ago; analysts expected DKK73.57 billion. 
Novo Nordisk A/S's reported EPS for the quarter was DKK3.79​.
The company reported quarterly net income of DKK16.74 billion.
Novo Nordisk A/S shares had risen by 6.7% this quarter and lost 16.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 4.8% in the last three months.​ 
In the last 30 days, three analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 7 "strong buy" or "buy," 19 "hold" and 6 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is  "buy."
Wall Street's median 12-month price target for Novo Nordisk A/S is DKK296.00, about 8.7% above its last closing price of DKK270.15
This summary was machine generated from LSEG data November 4 at 07:35 a.m. UTC. ​All figures in Danish crowns unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
4.82
3.79
Missed
Jun. 30 2026 
4.98
4.75
Missed
Mar. 31 2026 
5.33
6.63
Beat
Dec. 31 2025 
5.90
6.04
Beat